

Ref. No.: WOCK/SEC/SE/2026-27/031

10th August, 2026

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Press Release

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026.

A copy of the same will also be uploaded on the Company's website www.wockhardt.com

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: as above


Mumbai, Aug 10th, 2026

Wockhardt Reports PAT of Rs. 107 Cr for Q1 FY 27 Maintaining Positive Momentum

FINANCIAL HIGHLIGHTS

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter Results for Financial Year 2026-27, today.

Q1 FY 27		Growth
 INR 929 Cr. Revenue		26%
 INR 188 Cr. EBITDA		86%
 INR 116 Cr. PBT		>100%
 INR 107 Cr. PAT		>100%



Profit before tax Rs.116 Cr for Q1 FY27 as compared to Rs. (-) 109 Cr in the previous year.

Q1 FY27 Performance: Revenue growth of 26% compared to previous year, revenue of Rs.929 Cr in Q1 FY27 compared to Rs.738 Cr in the previous year. EBITDA growth of 86% in EBITDA in Q1 FY27 compared to previous year, EBITDA of Rs.188 Cr compared to Rs.101 Cr in the previous year.

Financial Performance:

Particulars	Q1 FY27	Q1 FY26	Q4 FY26
	Apr - Jun 2026	Apr - Jun 2025	Jan - Mar 2026
Total Revenue	929	738	965
EBITDA before R&D	222	128	224
EBITDA % to Sales	23.8%	17.4%	23.2%
R&D	34	27	28
R&D % to Sales	3.6%	3.7%	2.9%
EBITDA	188	101	196
EBITDA Margins %	20.2%	13.7%	20.3%
Exceptional Items	-	(97)	22
PBT	116	(109)	189
Profit After Tax	107	(108)	164
PAT Margins %	11.5%	-14.6%	17.0%

Biosimilar Highlights:



- The overall Biotech operations for the quarter stood at Rs.236 crore recording a growth of 112% vs Q1 FY26. This robust achievement is fuelled by our Emerging Market biotech segment growing at ~146% on Q1 FY26 with accelerated business opportunities and

strategic business partnerships, new deal acquisitions from our key markets like Brazil, Thailand, Egypt, Algeria and LATAM. Our India Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.

- The Company's strength lies in our robust and end to end well integrated Biotech infrastructure. Looking ahead, the upcoming launch of Insulin analogs over the next few years represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Business Highlights:

Region-wise Revenue Highlights:

Q4 FY26	Regions	Currency	Q1 FY27	Q1 FY26
	India & Emerging Market			
112	India Branded Business	INR Cr	156	129
79	India-Others	INR Cr	46	49
320	Emerging Market	INR Cr	263	161
	EU & UK			
29	UK	GBP Mn	27	27
10	Others	Euro Mn	11	9
965	Total revenue	INR Cr	929	738

- **India Branded Business** stood at Rs.156 crore in Q1 FY27 with a growth of 21% compared to the previous year. The India Business growth was aided by substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK) and the introduction of Regenerative Derma segment.
- **UK region** stood at Rs.343 crore in Q1 FY27 with a growth of 10% compared to the previous year.
- **Emerging Markets region** stood at Rs.263 crore in Q1 FY27 with a growth of 64% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
- **Irish region** stood at Rs.64 crore in Q1 FY27 with a growth of 28% compared to the previous year.

New Products Launch:

- 12 Filings, 9 Approvals and 5 launches in our International Business.
- Biosimilars 1 Filing and 3 Approvals and NCE - 1 Filing & 2 Approvals.
- Approval received for EMROK O and EMROK injection in Uganda.

Novel Antibiotics:

Key Updates:

Five Novel Antibiotics from Wockhardt completed Phase 3 Clinical Trials successfully: Emrok®, Emrok O®, Miquaf®, Zaynich® and Foviscu®.

❖ ZAYNICH®:



- **Approved in US:** On May 30, US FDA approved Zaynich for the treatment of cUTI including Pyelonephritis making it 1st ever India-discovery and developed drug gaining approval from US FDA.
- **Approved in India:** On May 28, US FDA approved Zaynich for the treatment of cUTI including Pyelonephritis making it 1st ever India-discovery and developed drug gaining approval from US FDA.
- **EMA review process:** It is progressing as planned. In response to the Marketing Authorization Application (MAA), the EMA has communicated that the submitted dossier is adequate for review for the proposed indications, including complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia/ventilator-associated pneumonia (**HAP/VAP**) and bloodstream infections (BSI).

- CDSCO Subject Expert Committee approved the clinical data on March 10, 2026; Full approval after CMC data review expected by Q3 FY 27.


❖ **EMROK®/ EMROK O®:**



- Growth rate of 29% vs previous year Q1 FY27.
- Continues to address critical unmet need in the treatment of difficult-to-manage Gram-positive infections, including bone and joint infections, diabetic foot infections, and pneumonia.
- On track to become the leading brands in the anti-MRSA therapy segment.

❖ **MIQNAF® NAFITHROMYCIN: approved and launched in India.**

- Removal of “supply condition” by DCGI – Now facilitates marketing access to wider patient population.
- Field force deployed to align with the supply condition removal for ease of drug access.
- Increasing acceptance within the clinical community owing to comprehensive coverage of pathogens and shorter course of therapy, facilitating antibiotic stewardship.



❖ **FOVISCU® (WCK 4282):**

- India Phase 3 Clinical Trial completed successfully. NDA Filing planned during Q3 FY27.
- Underwent combined Phase 2 and Phase 3 program with enrolment of 324 hospitalized cUTI and AP patients wherein more than half of the Enterobacterales isolates (51%) were ESBL-positive, and 34% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.

Intellectual Property Update:

1 Patent was filed during the quarter ended Q1 FY27 and the cumulative filings till date are 3291 and the Company holds 859 patents.

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

WOCKHARDT | **LIFE WINS**
DRUG DISCOVERY PROGRAMME
USFDA QIDP STATUS : 6 ANTI-BACTERIALS

Wockhardt is employing around ~3200 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 78% of its global revenues coming from international businesses.